Your browser is no longer supported. Please, upgrade your browser.
Settings
TRVN Trevena, Inc. daily Stock Chart
TRVN [NASD]
Trevena, Inc.
Index- P/E- EPS (ttm)-0.28 Insider Own0.30% Shs Outstand131.63M Perf Week46.07%
Market Cap382.98M Forward P/E- EPS next Y-0.19 Insider Trans0.00% Shs Float130.44M Perf Month31.98%
Income-27.00M PEG- EPS next Q-0.05 Inst Own15.30% Short Float10.44% Perf Quarter67.74%
Sales0.03M P/S12354.19 EPS this Y35.20% Inst Trans11.82% Short Ratio1.30 Perf Half Y348.28%
Book/sh0.50 P/B5.20 EPS next Y13.60% ROA-51.60% Target Price- Perf Year160.05%
Cash/sh0.37 P/C6.99 EPS next 5Y- ROE-72.50% 52W Range0.46 - 3.68 Perf YTD209.19%
Dividend- P/FCF- EPS past 5Y33.10% ROI- 52W High-29.35% Beta3.03
Dividend %- Quick Ratio16.20 Sales past 5Y- Gross Margin- 52W Low465.22% ATR0.22
Employees24 Current Ratio16.20 Sales Q/Q- Oper. Margin- RSI (14)70.64 Volatility14.21% 11.43%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.10% Profit Margin- Rel Volume1.58 Prev Close2.22
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume10.51M Price2.60
Recom2.00 SMA2045.19% SMA5028.26% SMA200117.57% Volume16,578,322 Change17.12%
Sep-14-20Initiated Guggenheim Buy $5
Aug-28-20Initiated Cantor Fitzgerald Overweight $5
May-31-19Resumed H.C. Wainwright Buy
Nov-05-18Downgrade H.C. Wainwright Buy → Neutral
Oct-12-18Downgrade Needham Buy → Hold
Oct-10-18Downgrade Jefferies Buy → Hold
Nov-08-17Reiterated Needham Buy $9 → $7
Oct-16-17Downgrade Barclays Overweight → Equal Weight $15 → $2.50
Oct-12-17Reiterated H.C. Wainwright Buy $8 → $7
May-08-17Reiterated Needham Buy $11 → $9
Feb-23-17Reiterated H.C. Wainwright Buy $11 → $8
Feb-22-17Reiterated FBR & Co. Outperform $13 → $8
Feb-02-17Initiated Ladenburg Thalmann Buy $15
Jan-09-17Initiated H.C. Wainwright Buy $11
Jan-05-17Initiated Oppenheimer Outperform
May-17-16Reiterated Needham Buy $14 → $11
May-17-16Reiterated FBR Capital Outperform $13 → $16
Mar-29-16Initiated FBR Capital Outperform $16
Sep-01-15Reiterated Wedbush Outperform $15 → $20
Aug-03-15Initiated Brean Capital Buy $14
Sep-18-20 09:20AM  
Sep-14-20 07:03PM  
10:33AM  
Sep-03-20 06:20PM  
Sep-02-20 07:00AM  
Aug-28-20 10:16AM  
Aug-26-20 07:00AM  
Aug-24-20 07:00AM  
Aug-20-20 07:36AM  
Aug-18-20 08:52AM  
Aug-14-20 01:42PM  
Aug-12-20 12:20PM  
09:27AM  
Aug-11-20 06:05PM  
04:01PM  
Aug-10-20 05:16PM  
06:30AM  
Aug-07-20 07:34AM  
Jul-16-20 08:56AM  
Jun-04-20 07:00PM  
Jun-03-20 09:41AM  
08:02AM  
Jun-02-20 11:31AM  
07:00AM  
May-22-20 11:30AM  
May-07-20 07:00AM  
May-06-20 11:30AM  
May-01-20 07:00AM  
Apr-23-20 07:00AM  
Apr-12-20 07:01AM  
Apr-07-20 09:19AM  
Mar-30-20 11:11AM  
Mar-12-20 07:01AM  
Mar-06-20 04:47PM  
Mar-05-20 05:00PM  
08:05AM  
07:01AM  
Feb-19-20 12:51PM  
Feb-13-20 07:00AM  
Feb-11-20 09:22AM  
Feb-10-20 09:43AM  
07:01AM  
Feb-05-20 07:00AM  
Jan-17-20 11:56AM  
Dec-23-19 02:55PM  
07:00AM  
Dec-12-19 07:00AM  
Nov-20-19 07:00AM  
07:00AM  
Nov-18-19 05:05PM  
Nov-06-19 03:47PM  
Nov-04-19 07:00AM  
Oct-21-19 10:30AM  
Oct-18-19 11:04AM  
Sep-27-19 07:00AM  
Sep-20-19 08:46AM  
Sep-06-19 11:53AM  
Sep-04-19 07:41AM  
Sep-03-19 02:56PM  
07:00AM  
Aug-29-19 11:41AM  
07:38AM  
Aug-28-19 04:01PM  
02:28PM  
Aug-07-19 07:00AM  
Jul-31-19 07:00AM  
Jul-19-19 10:50PM  
11:19AM  
Jun-27-19 07:00AM  
Jun-24-19 07:00AM  
Jun-20-19 12:36PM  
07:00AM  
May-31-19 10:50PM  
May-29-19 04:01PM  
May-23-19 11:24PM  
May-10-19 07:22AM  
07:00AM  
Apr-24-19 11:43AM  
Apr-15-19 10:50AM  
Apr-12-19 09:17AM  
08:00AM  
Mar-22-19 05:50PM  
Mar-20-19 07:53AM  
06:08AM  
Mar-19-19 05:53PM  
02:30PM  
Mar-18-19 09:30AM  
Mar-15-19 12:27PM  
11:25AM  
Mar-14-19 11:20AM  
11:13AM  
Mar-13-19 07:49AM  
07:00AM  
Mar-11-19 07:00AM  
Mar-04-19 03:00PM  
07:00AM  
Feb-08-19 10:20AM  
06:51AM  
Feb-07-19 09:00AM  
Feb-06-19 11:20AM  
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.